UBA1 is a potential cancer biomarker and therapeutic target that mediates immune evasion through JAK1 degradation, and targeted UBA1 inhibition synergizes with immune checkpoint blockade to enhance antitumor immunity and survival. Here, JAK1 is linked to cancer.